Kavanaugh A F, Schulze-Koops H, Davis L S, Lipsky P E
University of Texas Southwestern Medical Center at Dallas, 75235-8577, USA.
Arthritis Rheum. 1997 May;40(5):849-53. doi: 10.1002/art.1780400511.
To assess the safety and efficacy of a second course of treatment with a murine monoclonal antibody (MAb) to intercellular adhesion molecule 1 (ICAM-1; CD54) in active rheumatoid arthritis (RA).
In an open-label study, 8 patients who had previously received a course of anti-ICAM-1 MAb received a second course.
The second course of therapy was associated with adverse effects suggestive of immune complex formation. Such adverse effects were not seen during the initial course of therapy. Clinical efficacy associated with the second course of therapy was less than that observed in the first course.
Repeated courses of therapy with a murine MAb to ICAM-1 would probably not be a useful therapeutic strategy in patients with RA, probably because of its immunogenicity.
评估用抗细胞间黏附分子1（ICAM-1；CD54）鼠单克隆抗体（MAb）进行第二疗程治疗对活动期类风湿关节炎（RA）患者的安全性和有效性。
在一项开放标签研究中，8名先前接受过一个疗程抗ICAM-1 MAb治疗的患者接受了第二疗程治疗。
第二疗程治疗出现了提示免疫复合物形成的不良反应。在初始疗程中未观察到此类不良反应。第二疗程治疗的临床疗效低于第一疗程。
对RA患者重复使用抗ICAM-1鼠MAb进行治疗可能不是一种有效的治疗策略，这可能是由于其免疫原性。
